NovaBay Pharmaceuticals, Inc. (NBY)'s Neutrophase® Is Best In Class In Laboratory Study Of 19 Top Commercial Wound Cleansers
2/17/2014 8:39:13 AM
EMERYVILLE, Calif., Feb. 17, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic anti-microbial products, today announced that a new study in the journal Advances in Skin & Wound Care showed that the company's wound cleanser, NeutroPhase®*, achieved better results in lab tests than 18 other commercial products. Unlike any of the other products, NeutroPhase was able to kill bacteria in less than a minute.
Help employers find you! Check out all the jobs and post your resume.
comments powered by